RE:RE:ONCY presents 2 posters at ASCO 2024As there had been no first line treatment for mPDAC, in February 2024 the FDA resorted to approving an already established chemotherapy combination treatment for this rare disease condition. Notwithstanding this approval, there still exists an unmet treatment need for novel, effective and more beneficial treatments in this rare disease, such as is provided by the immunotherpy combination of pelareorep + atezolizumab + chemotherapy. Liposomal irinotecan, in combination with 5-FU/leucovorin, is already approved for people with metastatic pancreatic cancer that has continued to grow after being treated with another chemotherapy called gemcitabine (Gemzar®). Oxaliplatin has also been approved and used to treat other cancers for a long time.
NALIRIFOX is a combination of liposomal irinotecan, 5-FU/leucovorin and oxaliplatin. This combination has now been approved for a new group of patients, those with metastatic pancreatic cancer who have not had any other treatment. This is the first approval for a first-line treatment for metastatic pancreatic cancer in over ten years.
https://pancan.org/news/fda-approves-new-first-line-treatment-option-for-metastatic-pancreatic-cancer-what-you-need-to-know/